These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1872307)

  • 21. Microvascular basement membranes in diabetes mellitus.
    Tsilibary EC
    J Pathol; 2003 Jul; 200(4):537-46. PubMed ID: 12845621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current concepts of the pathogenesis of diabetic microangiopathy].
    Morell B
    Ther Umsch; 1983 Oct; 40(10):845-51. PubMed ID: 6648843
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effect of antiaggregants on the course of diabetic microangiopathy].
    Bokarev IN; Velikov VK; Zelenchuk NM; Shubina OI; Saltykov BB; Frolova AI; Polunin GS; Pirogova EP; Nikol'skaia VV; Davydova NG
    Ter Arkh; 1993; 65(3):78-81. PubMed ID: 8059393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits.
    Pagano PJ; Griswold MC; Ravel D; Cohen RA
    Diabetologia; 1998 Jan; 41(1):9-15. PubMed ID: 9498623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Desfaits AC; Serri O; Renier G
    Diabetes Care; 1998 Apr; 21(4):487-93. PubMed ID: 9571329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for glycemic control.
    Young CW
    Am J Med; 1985 Sep; 79(3B):8-11. PubMed ID: 3901746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1990; ():325-34. PubMed ID: 2195215
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostanoids and thromboxane A2 involvement in diabetic retinopathy.
    Naveh-Floman N; Moisseiev J
    Metab Pediatr Syst Ophthalmol; 1982; 6(3-4):321-5. PubMed ID: 6764248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelets and diabetic vascular disease.
    Paton RC; Passa P
    Diabete Metab; 1983 Dec; 9(4):306-12. PubMed ID: 6230270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of gliclazide beyond metabolic control.
    Ceriello A
    Metabolism; 2006 May; 55(5 Suppl 1):S10-5. PubMed ID: 16631804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antioxidants in the combined therapy of diabetic angiopathies].
    Bobyreva LE
    Eksp Klin Farmakol; 1998; 61(1):74-80. PubMed ID: 9575419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects.
    Camera A; Hopps E; Caimi G
    Minerva Endocrinol; 2007 Sep; 32(3):209-29. PubMed ID: 17912158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy?
    Giusti C
    Med Hypotheses; 2004; 63(2):235-8. PubMed ID: 15236781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypoglycemic agents of the 2d generation].
    Giulietti M
    Clin Ter; 1978 Jul; 86(2):179-81. PubMed ID: 743858
    [No Abstract]   [Full Text] [Related]  

  • 35. "Pathogenesis of diabetic microangiopathy"--its past, present and future horizon.
    Jali MV
    J Assoc Physicians India; 1985 Dec; 33(12):803-9. PubMed ID: 3915501
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapeutic targets in diabetic vasculopathy].
    Sánchez Ferrer CF
    An R Acad Nac Med (Madr); 2003; 120(4):659-69; discussion 669-74. PubMed ID: 15147053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic microangiopathy, genetics, environment, and treatment.
    Siperstein MD
    Am J Med; 1988 Nov; 85(5A):119-30. PubMed ID: 3057889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diabetic microangiopathy--pathogenesis].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1991 Feb; 49 Suppl():25-33. PubMed ID: 1903463
    [No Abstract]   [Full Text] [Related]  

  • 39. Microangiopathy in diabetes mellitus: II. Features, complications and investigation.
    Shami SK; Chittenden SJ
    Diabetes Res; 1991 Aug; 17(4):157-68. PubMed ID: 1823636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.